Oragenics INC (OGEN) — SEC Filings

Overview

Oragenics INC (OGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 13, 2026: On April 13, 2026, Oragenics Inc. filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with the primary document being the 8-K form itself, along with an exhibit EX-99.1 and associated graphic files. The company's mailing and business address is in Lakew

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 3 bearish, 44 neutral, 3 mixed. The dominant filing sentiment for Oragenics INC is neutral.

Filing Type Overview

Oragenics INC (OGEN) has filed 32 8-K, 5 10-Q, 4 S-1/A, 2 S-1, 1 DEFA14A, 2 DEF 14A, 1 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jul 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Oragenics Inc. Files 8-K with Financials and Exhibits — 8-K · Apr 13, 2026 Risk: low
  On April 13, 2026, Oragenics Inc. filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with the primary document b
• Oragenics Reports Director/Officer Changes & Financials — 8-K · Dec 15, 2025 Risk: medium
  Oragenics, Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing covers the departure of directors or certain officers, t
• 8-K Filing — 8-K · Nov 12, 2025
• Oragenics' Cash Surges on $15.2M Offering, But Losses Persist — 10-Q · Nov 7, 2025 Risk: high
  Oragenics Inc. reported a net loss of $7.56 million for the nine months ended September 30, 2025, compared to a net loss of $7.22 million for the same period in
• Oragenics Files 8-K on Agreement and Listing Concerns — 8-K · Oct 21, 2025 Risk: high
  Oragenics, Inc. filed an 8-K on October 21, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet listing standards. The
• Oragenics Files 8-K: Director/Officer Changes & Financials — 8-K · Sep 2, 2025 Risk: medium
  Oragenics, Inc. filed an 8-K on September 2, 2025, reporting events as of September 1, 2025. The filing indicates changes related to the departure of directors
• Oragenics Inc. Files 8-K Report — 8-K · Aug 11, 2025 Risk: low
  On August 11, 2025, Oragenics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Oragenics Reports No Revenue, Deepening Losses Amid Capital Raises — 10-Q · Aug 8, 2025 Risk: high
  Oragenics Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, indicating its pre-commercial stage
• Oragenics Files 8-K with Material Agreements and Bylaw Changes — 8-K · Jul 2, 2025 Risk: medium
  On June 30, 2025, Oragenics, Inc. filed an 8-K report detailing several key events. These include entering into a material definitive agreement, modifications t
• Oragenics Files S-1/A for Continuous Securities Offering — S-1/A · Jun 30, 2025 Risk: high
  ORAGENICS INC (OGEN) filed an S-1/A on June 30, 2025, for a delayed and continuous offering of securities under Rule 415, indicating a potential capital raise.
• Oragenics Files S-1 for Continuous Offering, Signaling Funding Needs — S-1 · Jun 23, 2025 Risk: medium
  Oragenics Inc. (OGEN) filed an S-1 registration statement on June 23, 2025, for a delayed or continuous offering of securities under Rule 415. The company, a no
• Oragenics Files 8-K: Security Holder Rights & Bylaws Amended — 8-K · May 28, 2025 Risk: medium
  Oragenics, Inc. filed an 8-K on May 28, 2025, reporting material modifications to security holder rights and amendments to its articles of incorporation or byla
• 8-K Filing — 8-K · May 20, 2025
• Oragenics Files Q1 2025 10-Q Report — 10-Q · May 9, 2025 Risk: medium
  Oragenics Inc. filed its Q1 2025 10-Q report on May 9, 2025, covering the period ending March 31, 2025. The company, based in Sarasota, FL, operates in the phar
• Oragenics Files 8-K: Material Agreements, Officer Changes, Shareholder Votes — 8-K · May 2, 2025 Risk: medium
  On May 2, 2025, Oragenics, Inc. filed an 8-K report detailing several key events. These include the entry into a material definitive agreement, changes in direc
• Oragenics Inc. Files Proxy Materials — DEFA14A · Apr 11, 2025 Risk: low
  Oragenics Inc. filed a Definitive Additional Materials (DEFA14A) on April 11, 2025, related to its proxy statement. The filing indicates no fee was required for
• Oragenics Inc. Files 8-K Report — 8-K · Apr 9, 2025 Risk: low
  On April 9, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material e
• Oragenics Inc. Executive Compensation Revealed — DEF 14A · Apr 1, 2025 Risk: low
  Oragenics Inc. filed a DEF 14A on April 1, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information
• Oragenics Inc. Files 8-K Report — 8-K · Mar 27, 2025 Risk: low
  On March 27, 2025, Oragenics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosur
• Oragenics Inc. Files 2024 Annual Report — 10-K · Mar 14, 2025 Risk: medium
  Oragenics Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting its financial position and business operations. The company, headquartered
• Oragenics Inc. Files 8-K Report — 8-K · Mar 6, 2025 Risk: low
  On March 6, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Oragenics Files 8-K on Shareholder Nominations & Financials — 8-K · Feb 18, 2025 Risk: low
  Oragenics, Inc. filed an 8-K on February 18, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11 and including financial statements
• Oragenics Files 8-K Report — 8-K · Feb 5, 2025 Risk: low
  On February 5, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updat
• Oragenics Files 8-K with Financials and Exhibits — 8-K · Jan 21, 2025 Risk: low
  On January 21, 2025, Oragenics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicating routine
• Oragenics Reports Governance Changes and New Agreements — 8-K · Jan 17, 2025 Risk: medium
  On January 15, 2025, Oragenics, Inc. reported a material definitive agreement, the departure of directors or certain officers, and the election of directors. Th
• Oragenics Files S-1/A Amendment for Securities Registration — S-1/A · Jan 8, 2025 Risk: medium
  Oragenics, Inc. filed a pre-effective amendment (No. 2) to its Form S-1 registration statement on January 8, 2025, for the purpose of registering securities. Th
• Oragenics Files S-1/A Amendment — S-1/A · Dec 31, 2024 Risk: medium
  Oragenics, Inc. filed a Pre-Effective Amendment No. 1 to its Form S-1 Registration Statement on December 31, 2024. This filing relates to the registration of se
• Oragenics Files S-1 for Potential Securities Offering — S-1 · Dec 18, 2024 Risk: medium
  Oragenics Inc. filed an S-1 registration statement on December 18, 2024, indicating plans to offer securities. The company, incorporated in Florida with its pri
• Oragenics Announces Director Changes and New CMO — 8-K · Dec 16, 2024 Risk: medium
  Oragenics, Inc. announced on December 11, 2024, several key events including the departure of director Dr. David G. Murdock, the election of new directors Dr. M
• Oragenics Terminates Material Definitive Agreement — 8-K · Nov 29, 2024 Risk: medium
  Oragenics, Inc. filed an 8-K on November 29, 2024, reporting the termination of a material definitive agreement as of November 26, 2024. The filing also include
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Oragenics Inc. Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Oragenics Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including its prefe
• Oragenics Files 2023 Proxy Statement — DEF 14A · Oct 31, 2024 Risk: low
  Oragenics, Inc. filed its definitive proxy statement (DEF 14A) on October 31, 2024, for its 2023 Annual Meeting of Shareholders. The filing provides details reg
• Oragenics Inc. Files 8-K Report — 8-K · Oct 18, 2024 Risk: low
  On October 18, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and
• Oragenics Inc. Files 8-K Report — 8-K · Oct 16, 2024 Risk: low
  On October 15, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and E
• Oragenics Inc. Files 8-K for Material Definitive Agreement — 8-K · Oct 15, 2024 Risk: medium
  On October 11, 2024, Oragenics Inc. entered into a material definitive agreement. The company, incorporated in Florida with its principal executive offices in S
• Oragenics Inc. Files 8-K Report — 8-K · Oct 9, 2024 Risk: low
  On October 9, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns the company's financial statements and exhibits, indicating a routine dis
• Oragenics Announces Board and Executive Changes — 8-K · Sep 20, 2024 Risk: medium
  Oragenics, Inc. announced on September 19, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of
• SC 13G Filing — SC 13G · Sep 11, 2024
• Oragenics Files 8-K: Material Agreement, Other Events — 8-K · Sep 5, 2024 Risk: medium
  On September 4, 2024, Oragenics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial stateme
• Oragenics Files S-1/A Amendment — S-1/A · Sep 3, 2024 Risk: low
  Oragenics, Inc. filed an S-1/A amendment on September 3, 2024, regarding its registration statement. The filing details its corporate information, including its
• Oragenics Files 8-K with Corporate Updates — 8-K · Aug 21, 2024 Risk: low
  Oragenics, Inc. filed an 8-K on August 21, 2024, reporting other events and financial statements. The filing details the company's corporate structure, includin
• Oragenics Faces Delisting Concerns — 8-K · Aug 16, 2024 Risk: high
  Oragenics, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicate
• Oragenics Inc. Files 8-K with Financial Statements — 8-K · Aug 14, 2024 Risk: low
  On August 14, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclos
• Oragenics Files 8-K Report — 8-K · Aug 12, 2024 Risk: low
  On August 12, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific finan
• Oragenics Inc. Files Q2 2024 10-Q Report — 10-Q · Aug 9, 2024 Risk: low
  Oragenics Inc. filed its 10-Q for the period ending June 30, 2024. The company, based in Sarasota, Florida, operates in the pharmaceutical preparations sector.
• Oragenics Inc. Files 8-K Report — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Oragenics Inc. Files 8-K Report — 8-K · Jul 22, 2024 Risk: low
  On July 22, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates
• Oragenics Files 8-K Report — 8-K · Jul 10, 2024 Risk: low
  On July 10, 2024, Oragenics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates

Risk Profile

Risk Assessment: Of OGEN's 45 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Oragenics INC's most recent 10-Q filing (Nov 7, 2025):

• Revenue: N/A
• Net Income: $ -7.56M
• EPS: $ -5.16
• Debt-to-Equity: N/A
• Cash Position: $11.40M
• Operating Margin: N/A
• Total Assets: $12.71M
• Total Debt: $0.39M

Key Executives

• Janet Huffman
• Mark A. Catchur, Esq.
• Julio C. Esquivel, Esq.
• Ralph V. DeMartino, Esq.
• Marc Rivera, Esq.
• Michael Redmond
• Mark A. Catchur
• Ralph V. DeMartino
• Dr. David G. Murdock
• Dr. Michael J. McShane
• Mr. David M. S. Johnson
• J. Michael Redmond

Industry Context

Oragenics operates in the biotechnology and pharmaceutical sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on external financing to fund their operations and clinical trials, facing intense competition and the risk of pipeline failures.

Top Tags

sec-filing (10) · financials (8) · 8-k (8) · 8-K (6) · corporate-governance (5) · regulatory-filing (5) · filing (4) · management-change (4) · material-agreement (4) · 10-Q (4)

Key Numbers

• 8-K form size: 41790 — Size of the main 8-K document in bytes.
• EX-99.1 size: 24987 — Size of Exhibit 99.1 in bytes.
• Complete submission text file size: 284998 — Size of the complete submission text file in bytes.
• Cash and cash equivalents: $11.40M — Increased from $864,840 at December 31, 2024, due to financing activities.
• Net loss for nine months ended Sep 30, 2025: $7.56M — Increased from $7.22 million in the prior year, indicating continued unprofitability.
• Accumulated deficit: $224.34M — As of September 30, 2025, highlighting significant historical losses.
• Net proceeds from Series H Preferred Stock and warrants: $15.2M — Raised in July 2025, providing critical liquidity.
• Research and development expenses: $1.72M — Decreased by 29.7% for the nine months ended September 30, 2025, compared to $2.45 million in 2024.
• General and administrative expenses: $5.14M — Increased by 8.2% for the nine months ended September 30, 2025, compared to $4.75 million in 2024.
• Common stock shares outstanding: 4,168,223 — As of November 6, 2025, reflecting recent equity activity.
• Reverse stock split ratio: 1-for-30 — Effected on June 3, 2025, to increase per-share price.
• Revenue: $0 — for the three and six months ended June 30, 2025, indicating pre-commercial stage
• Retained Earnings: -$204,000,000 — as of June 30, 2025, reflecting accumulated losses
• Registration Statement Number: 333-288225 — Identifies the specific S-1/A filing for ORAGENICS INC.
• Filing Date: 2025-06-30 — Date the S-1/A was filed with the SEC.

Related Companies

ORGN

Frequently Asked Questions